| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 6.2 | 6.5 | 5.2 |
| Other income | 0.1 | 0.1 | 0.1 |
| Total income | 6.3 | 6.7 | 5.4 |
| Profit before exceptional items & tax | -0.0 | -0.7 | 0.5 |
| Profit before tax | -0.0 | -0.7 | 0.5 |
| Net profit | -0.0 | -0.7 | 0.5 |
| Operating margin | 0.0% | -10.4% | 9.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +19.20% |
|---|---|
| Operating profit, year on year | -125.00% |
| Operating profit, quarter on quarter | +87.50% |
BSE results filing, NSE: ASPIRA. Figures extracted from the filing.
Aspira Pathlab & Diagnostics Ltd: key numbers
- Share price
- ₹130.02
- Market cap
- ₹133.8 Cr
- Revenue (annual)
- ₹24.98 Cr
- Net profit (annual)
- ₹0.05 Cr
- P/E (TTM)
- -295.7×Sector 57.8×
- Promoter holding
- 46.58%+28.19% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aspira Pathlab & Diagnostics Ltd
All →Aspira Pathlab & Diagnostics Annual General Meeting
Aspira Pathlab & Diagnostics held its 53rd Annual General Meeting on September 25, 2026, where members deliberated on financial statements and various directorial appointments.
Aspira Pathlab & Diagnostics Promoter Buying: ₹0.01 Cr
Promoter Jay Arvind Bhanushali acquired 1,387 equity shares of Aspira Pathlab & Diagnostics Ltd through market purchase, increasing their stake from 7.25% to 7.27%.
- Value
- ₹0.01 Cr
- Promoter stake change
- +0.02%
Aspira Pathlab & Diagnostics Promoter Buying
Promoter Jay Arvind Bhanushali acquired 1,387 shares of Aspira Pathlab & Diagnostics Ltd via an open-market transaction, increasing his stake by 0.02%.
- Promoter stake change
- +0.02%
Aspira Pathlab & Diagnostics Promoter Buying: ₹0 Cr
Promoter Jay Arvind Bhanushali acquired 74 shares of Aspira Pathlab & Diagnostics Ltd via market purchase on September 10, 2026.
- Value
- ₹0.00 Cr
Aspira Pathlab & Diagnostics Fund Raise of ₹65 Cr
Aspira Pathlab approved raising funds of up to ₹65 Crore via a Rights Issue to eligible shareholders. A committee was constituted to oversee the process.
- Value
- ₹65.00 Cr
Aspira Pathlab & Diagnostics Board Meeting Date
Aspira Pathlab will hold a board meeting on 12 Sep 2026 to consider a capital raise via preferential issue, private placement, or rights issue. No amount or terms are yet specified.